Top in cardiology: BP remains strongest CVD risk factor; study shows benefits of omega-3
Click Here to Manage Email Alerts
Global cardiovascular mortality increased through 2022, with BP remaining the largest contributor to CVD worldwide, according to an almanac-style report published in the Journal of the American College of Cardiology.
“Cardiovascular diseases are a persistent challenge that lead to an enormous number of premature and preventable deaths,” one of the authors of the report said in a press release.
It was the top story in cardiology last week.
In another top story, foods rich in omega-3 polyunsaturated fatty acids, including fish, nuts, flax seeds and leafy vegetables, may reduce risk for heart disease in those with a family history of CVD, according to data published in Circulation.
Read these and more top stories in cardiology below:
Blood pressure remains largest contributor to global CVD; mortality on the rise
Global cardiovascular mortality and the prevalence of important cardiometabolic risk factors increased through 2022, with high BP remaining the strongest contributor, according to the 2023 update to the Global Burden of Disease special report on CVD. Read more.
Omega-3 fatty acid intake may lower CV risk in those with family history of heart disease
Higher intake of omega-3 polyunsaturated fatty acids, or omega-3s, may reduce risk for heart disease in those with a family history of CVD, according to data published in Circulation. Read more.
X-rays and the evolving standard of care for hospital staff
It seems long ago now that so much has changed, but just a few decades ago, interventional cardiologists, electrophysiologists and others who work daily with X-ray machines lived in a very different world. Read more.
FDA approves expanded indications for bempedoic acid and combination tablet
Esperion announced that the FDA granted an updated indication for bempedoic acid and bempedoic acid plus ezetimibe for the treatment of primary hyperlipidemia in eligible patients with genetic hyperlipidemia or atherosclerotic CVD. Read more.
FDA approves first pulsed field AF ablation system
Medtronic announced the FDA approved its pulsed field ablation system for the treatment of both paroxysmal and persistent atrial fibrillation via pulmonary vein isolation. Read more.